Int. J. Environ. Res. Public Health 2010, 7 1887 27. Mundt, B.; Wirth, T.; Zender, L.; Waltemathe, M.; Trautwein, C.; Manns, M.P.; Kuhnel, F.; Kubicka, S. Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 2005, 54, 1590–1596. 28. Pritchard, M.T.; McMullen, M.R.; Stavitsky, A.B.; Cohen, J.I.; Lin, F.; Medof, M.E.; Nagy, L.E. Differential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in mice. Gastroenterology 2007, 132, 1117–1126. 29. Arteel, G.E. Silencing a killer among us: ethanol impairs immune surveillance of activated stellate cells by natural killer cells. Gastroenterology 2008, 134, 351–353. 30. Stewart, S.; Prince, M.; Bassendine, M.; Hudson, M.; James, O.; Jones, D.; Record, C.; Day, C.P. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J. Hepatol. 2007, 47, 277–283. 31. Cotrim, H.P.; Freitas, L.A.; Alves, E.; Almeida, A.; May, D.S.; Caldwell, S. Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients. Eur. J. Gastroenterol. Hepatol. 2009, 21, 969–972. 32. Butterworth, R.F. Hepatic encephalopathy—A serious complication of alcoholic liver disease. Alcohol Res. Health 2003, 27, 143–145. 33. Bergheim, I.; McClain, C.J.; Arteel, G.E., Treatment of alcoholic liver disease. Dig. Dis. 2005, 23, 275–284. 34. Angulo, P. Noninvasive assessment of fibrosis and steatosis in NASH and ASH. Gastroenterol. Clin. Biol. 2009, 33, 940–948. 35. Tiniakos, D.G. Liver biopsy in alcoholic and non-alcoholic steatohepatitis patients. Gastroenterol. Clin. Biol. 2009, 33, 930–939. 36. Sebastiani, G. Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. World J. Gastroenterol. 2009, 15, 2190–2203. 37. Liaw, Y.F.; Chu, C.M. Hepatitis B virus infection. Lancet 2009, 373, 582–592. 38. Forrest, E. H.; Evans, C.D.; Stewart, S.; Phillips, M.; Oo, Y.H.; McAvoy, N.C.; Fisher, N.C.; Singhal, S.; Brind, A.; Haydon, G.; O'Grady, J.; Day, C.P.; Hayes, P.C.; Murray, L.S.; Morris, A.J. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005, 54, 1174–1179. 39. Ong, J.P.; Mullen, K.D. Hepatic encephalopathy. Eur J Gastroenterol Hepatol 2001, 13, 325–334. 40. Jonas, S.; Al-Abadi, H.; Benckert, C.; Thelen, A.; Hippler-Benscheid, M.; Saribeyoglu, K.; Radtke, B.; Pratschke, J.; Neuhaus, P. Prognostic significance of the DNA-index in liver transplantation for hepatocellular carcinoma in cirrhosis. Ann. Surg. 2009, 250, 1008–1013. 41. Sheth, M.; Riggs, M.; Patel, T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol. 2002, 2, 2. 42. Neuberger, J., Developments in liver transplantation. Gut 2004, 53, 759–768. 43. Johnson, B.A., Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem. Pharmacol. 2008, 75, 34–56.